Reply to the comment by Skrobik et al.
de Rooij
Sophia
S
de Jonge
Evert
E
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D016638:Critical Illness; D003693:Delirium / Q000188:drug therapy*; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000077152:Olanzapine; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D006220:Haloperidol; D000077152:Olanzapine